(Total Views: 487)
Posted On: 01/04/2024 3:45:20 AM
Post# of 155150
at least from 2020, it was not discussed, at least not that I remember.
apparently, blipping was an issue that was partially addressed by increasing dose from 525mg to 700mg.
the "extra" leronlimab would then occupy the new CCR5 on the new CD4+ T Lymphocytes.
This improved the situation, but still permitted 5% to continue to blip whiich never would have been satisfactory for approval in monotherapy.
apparently, blipping was an issue that was partially addressed by increasing dose from 525mg to 700mg.
the "extra" leronlimab would then occupy the new CCR5 on the new CD4+ T Lymphocytes.
This improved the situation, but still permitted 5% to continue to blip whiich never would have been satisfactory for approval in monotherapy.
(3)
(0)
